HEMA Biologics™ Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw]
HEMA Biologics, LLC, (“HEMA Biologics”) today announced that the U.S. Food and Drug Administration (FDA) approved SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] as the first bypassing agent in over 20 years for adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
--April 6, 2020--
On January 9, 2017, HEMA Biologics, LLC announced Food and Drug Administration (FDA) acceptance of the Biologics License Application (BLA), for what could become their first commercial treatment for rare bleeding disorders in the United States.
--April 10, 2018--
This August was our second year at NHF’s Annual Meeting — an incredible venue for meeting the community and learning more about the day-to-day experience of living with a bleeding disorder.
--August 28, 2017--
It was hard to feel alone in the lone star state while surrounded by the more than 800 passionate attendees of this year’s Texas Bleeding disorders conference
--August 7, 2017--
This April, Hema Biologics™ had a great time interacting with the hemophilia community at HFA’s annual symposium. At the booth, we spoke with some of the 1100 participants who came to the event.
--April 10, 2017--
Every March is a chance to spread knowledge and awareness about bleeding disorders.
--March 15, 2017--
LOUISVILLE, Ky., Jan. 9, 2017 /PRNewswire/ -- HEMA Biologics, LLC announced that the FDA has accepted the BLA for their first potential product for commercialization in the United States.
--January 9, 2017--
We look forward to being at HFA and meeting the community. If you plan to attend, visit us at Booth 16.
--December 1, 2016--
Sign up to learn more about our focus on the rare bleeding disorder community